Methods
Here, we present the findings from a virtual meeting held in May 2020
attended by nine European Experts in AD. An updated consensus guidance
was developed based on a review of the latest available evidence on the
use of topical pimecrolimus 1% cream in infants aged between 3 months
to 2 years from clinical trials, including the results from 5-year
PETITE study which assessed the long-term safety and efficacy of
pimecrolimus versus TCS in over 2,000 infants. Additionally,
post-marketing surveillance and epidemiological studies were critically
evaluated. Ultimately, the comprehensive appraisal of the evidence was
combined with the opinion of the Expert Panel on the prevailing medical
need for safe and effective treatment options in infants with AD to
decrease the significant disease burden and improve the quality of life
(QoL) of patients and their families.